Technical Analysis for CBLI - Cleveland BioLabs, Inc.

Grade Last Price % Change Price Change
grade F 1.32 -4.35% -0.06
CBLI closed down 4.35 percent on Wednesday, January 16, 2019, on 46 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Flat
See historical CBLI trend table...

Date Alert Name Type % Chg
Jan 16 Fell Below 20 DMA Bearish 0.00%
Jan 16 Calm After Storm Range Contraction 0.00%
Jan 16 Inside Day Range Contraction 0.00%
Jan 16 Wide Bands Range Expansion 0.00%
Jan 15 20 DMA Support Bullish -4.35%
Jan 15 Wide Bands Range Expansion -4.35%
Jan 14 50 DMA Resistance Bearish -7.69%
Jan 14 1,2,3 Retracement Bearish Bearish Swing Setup -7.69%
Jan 14 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -7.69%
Jan 14 Crossed Above 20 DMA Bullish -7.69%

Older signals for CBLI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Cleveland BioLabs, Inc., a clinical-stage biotechnology company, engages in the research, development, and commercialization of products that have the potential to treat cancer, reduce death from total body irradiation, and counteract the genotoxic effects of radio- and chemotherapies for oncology patients. Its lead drug is Entolimod, which is being developed for radiation countermeasure and cancer treatment. The company's products candidates also include CBL0102, which is undergoing a Phase I safety and tolerability study in patients with liver metastases of solid tumors of epithelial origin, or primary advanced hepatic carcinoma; and CBL0137, which is in multi-center, single agent, dose escalation Phase I study of the oral formulation in subjects with advanced solid tumors. In addition, it has pre-clinical stage products candidates, such as CBLB612, an inducer and mobilizer of hematopoietic stem cells; Revercom, a cancer drug candidate comprising a liposome-packaged proprietary small molecule named Reversan; Mobilan, a nanoparticle-formulated recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand, flagellin; Arkil, a prospective treatment for prostate cancer; Antimycon, a proprietary small molecule lead compound generated to selectively target and inactivate oncoproteins of the Myc family; and Xenomycin family of compounds, which have a range of potential applications as antimicrobial and anti-fungal agents. The company has license agreements and collaborations with the Cleveland Clinic, Roswell Park Cancer Institute, the Children's Cancer Institute Australia, and the Armed Forces Radiobiology Research Institute. Cleveland BioLabs, Inc. was founded in 2003 and is headquartered in Buffalo, New York.
Is CBLI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.005
52 Week Low 1.0
Average Volume 9,215
200-Day Moving Average 2.1668
50-Day Moving Average 1.5974
20-Day Moving Average 1.3263
10-Day Moving Average 1.3205
Average True Range 0.1689
ADX 33.96
+DI 22.4815
-DI 23.8089
Chandelier Exit (Long, 3 ATRs ) 1.3633
Chandelier Exit (Short, 3 ATRs ) 1.5067
Upper Bollinger Band 1.6366
Lower Bollinger Band 1.016
Percent B (%b) 0.49
BandWidth 46.791827
MACD Line -0.0826
MACD Signal Line -0.1092
MACD Histogram 0.0267
Fundamentals Value
Market Cap 14.89 Million
Num Shares 11.3 Million
EPS -0.67
Price-to-Earnings (P/E) Ratio -1.97
Price-to-Sales 12.32
Price-to-Book 7.79
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.56
Resistance 3 (R3) 1.58 1.53 1.52
Resistance 2 (R2) 1.53 1.47 1.52 1.51
Resistance 1 (R1) 1.42 1.43 1.40 1.40 1.49
Pivot Point 1.37 1.37 1.35 1.36 1.37
Support 1 (S1) 1.26 1.31 1.24 1.24 1.15
Support 2 (S2) 1.21 1.27 1.20 1.13
Support 3 (S3) 1.10 1.21 1.12
Support 4 (S4) 1.08